1286238-55-8

Basic information

• Product Name: 3-Amino-6-[4-[[2-(dimethylamino)-1-methylethyl]sulfonyl]phenyl]-N-phenyl-2-pyrazinecarboxamide
• Synonyms: 3-Amino-6-[4-[[2-(dimethylamino)-1-methylethyl]sulfonyl]phenyl]-N-phenyl-2-pyrazinecarboxamide;2-PyrazinecarboxaMide, 3-aMino-6-[4-[[2-(diMethylaMino)-1-Methylethyl]sulfonyl]phenyl]-N-phenyl-;3-amino-6-[4-[1-(dimethylamino)propan-2-ylsulfonyl]phenyl]-N-phenylpyrazine-2-carboxamide
• CAS NO: 1286238-55-8
• Molecular Formula: C₂₂H₂₅N₅O₃S
• Molecular Weight: 440
• Mol File: 1286238-55-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Amino-6-[4-[[2-(dimethylamino)-1-methylethyl]sulfonyl]phenyl]-N-phenyl-2-pyrazinecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-6-[4-[[2-(dimethylamino)-1-methylethyl]sulfonyl]phenyl]-N-phenyl-2-pyrazinecarboxamide(1286238-55-8)
• EPA Substance Registry System: 3-Amino-6-[4-[[2-(dimethylamino)-1-methylethyl]sulfonyl]phenyl]-N-phenyl-2-pyrazinecarboxamide(1286238-55-8)

Safety Data

• Hazardous Substances Data: 1286238-55-8(Hazardous Substances Data)

Upstream product

• 26732-25-2 1-bromo-4-(2-chloroethylsulfonyl)benzene 
• 486424-37-7 3-amino-6-bromo-pyrazine-2-carboxylic acid 
• 6966-01-4 methyl 3-amino-6-bromopyrazine-2-carboxylate 
• 1232424-47-3 2-(4-bromophenyl)sulfonyl-N,N-dimethyl-propan-1-amine 
• 1232424-38-2 2-(4-bromophenyl)sulfonyl-N,N-dimethyl-ethanamine 
• 16298-03-6 Methyl 3-amino-2-pyrazinecarboxylate 

Relevant articles and documents

Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents

DNA-damaging agents are among the most frequently used anticancer drugs. However, they provide only modest benefit in most cancers. This may be attributed to a genome maintenance network, the DNA damage response (DDR), that recognizes and repairs damaged DNA. ATR is a major regulator of the DDR and an attractive anticancer target. Herein, we describe the discovery of a series of aminopyrazines with potent and selective ATR inhibition. Compound 45 inhibits ATR with a Ki of 6 nM, shows >600-fold selectivity over related kinases ATM or DNA-PK, and blocks ATR signaling in cells with an IC50 of 0.42 μM. Using this compound, we show that ATR inhibition markedly enhances death induced by DNA-damaging agents in certain cancers but not normal cells. This differential response between cancer and normal cells highlights the great potential for ATR inhibition as a novel mechanism to dramatically increase the efficacy of many established drugs and ionizing radiation.